Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
Poolbeg Pharma PLC (AIM:POLB) Immunomodulator I Patent Portfolio Strengthened
Notice of allowance for patent grant in Japan
Poolbeg Pharma PLC (AIM:PLOB) Immunomodulator I Patent Opposition Withdrawal
An important step in the continued protection of Poolbeg’s patent family
Poolbeg Pharma PLC (AIM:POLB) Interim results for the six months to 30 June 2023
Significant progress made and well positioned for future growth
Evgen Pharma (AIM:EVG) welcomes a new chairman and Chief Financial Officer (CFO).
Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Evgen Pharma (AIM:EVG) celebrates the potential new formulation of its leading candidate.
Evgen Pharma PLC (AIM: EVG) has revealed the conclusive data from its Phase 1b study, which evaluated the new enteric-coated tablet formulation of its primary drug, SFX-01.
Evgen Pharma (AIM:EVG) shifts focus towards more lucrative collaborations as their partnership with JuvLife concludes.
Evgen Pharma PLC (AIM: EVG), a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.
Poolbeg Pharma PLC (AIM:POLB) AI led programme identifies influenza drug targets
Successful Artificial Intelligence led programme identifies multiple influenza drug targets
Poolbeg Pharma PLC (AIM:POLB) Oral Vaccine Programme Moves Forward
Next-Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding
Poolbeg Pharma PLC – Board Appointment
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s